TScan Therapeutics, Inc. TCRX
Set alert
As of Nov 3, 12:55 PM ET
- YTD
- -80.94%
- 1 year
- -84.63%
- Open
- 0.1768
- Prev close
- 0.1791
- Mkt cap
- 12.92M
- Vol
- 129.32K
- Avg vol
- 738.67K
- EPS
- -0.91
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.1768
- High
- 0.1907
- Forward P/E
- -2.33
- Beta
- 0.78
- Short ratio
- 9.02
- Inst. own
- 86.11%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 4.58
- 200-d avg
- 6.31
- 1y target
- 12.14
5D chart
Signals (99)
| Name | Time | Ago |
|---|---|---|
| SMA: Bearish | Nov 2, 3:45 PM | 21 hours ago |
| SMA: Bullish | Nov 2, 3:30 PM | 21 hours ago |
| SMA: Bearish | Nov 2, 1:30 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 1:20 PM | 23 hours ago |
| SMA: Bearish | Nov 2, 12:45 PM | 1 day ago |
| SMA: Bearish | Nov 2, 12:30 PM | 1 day ago |
| MACD: Sell Signal | Nov 2, 12:30 PM | 1 day ago |
| SMA: Bullish | Nov 2, 11:50 AM | 1 day ago |
| MACD: Buy Signal | Nov 2, 11:50 AM | 1 day ago |
| SMA: Bearish | Nov 2, 11:45 AM | 1 day ago |
| SMA: Bullish | Nov 2, 11:40 AM | 1 day ago |
| SMA: Bearish | Nov 2, 11:35 AM | 1 day ago |
| MACD: Sell Signal | Nov 2, 11:35 AM | 1 day ago |
| SMA: Bullish | Nov 2, 10:45 AM | 1 day ago |
| SMA: Bearish | Nov 2, 10:30 AM | 1 day ago |
| RSI: Overbought | Nov 2, 9:55 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:50 AM | 1 day ago |
| SMA: Bullish | Nov 2, 9:45 AM | 1 day ago |
| MACD: Buy Signal | Nov 2, 9:40 AM | 1 day ago |
| MACD: Sell Signal | Nov 2, 9:35 AM | 1 day ago |
Newest 20 of 99.
News
1 week ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 19.3% to $1.14 during Tuesday's after-market session. The company's market cap stands at $1.8 million. Edesa Biotech (NASDAQ:EDSA)…
-
2 weeks ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Vivos Therapeutics (NASDAQ:VVOS) stock increased by 17.9% to $0.16 during Monday's after-market session. The market value of their outstanding shares is at $2.8 million. SCWorx (NASDAQ:WORX)…
1 month ago defenseworld.net
Contrasting TScan Therapeutics (NASDAQ:TCRX) and BioNTech (NASDAQ:BNTX)
BioNTech (NASDAQ: BNTX - Get Free Report) and TScan Therapeutics (NASDAQ: TCRX - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses…
-
1 month ago benzinga.com
HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
HC Wainwright & Co. analyst Andres Y. Maldonado downgrades TScan Therapeutics (NASDAQ:TCRX) from Buy to Neutral and lowers the price target from $7 to $1.
-
2 months ago benzinga.com
Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1
Wedbush analyst David Nierengarten downgrades TScan Therapeutics (NASDAQ:TCRX) from Outperform to Neutral and lowers the price target from $5 to $1.
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers bioAffinity Technologies (NASDAQ:BIAF) stock moved upwards by 54.3% to $10.17 during Wednesday's regular session. The company's market cap stands at $3.9 million. Gelteq (NASDAQ:GELS) shares…
2 months ago seekingalpha.com
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
TScan Therapeutics, Inc. (TCRX) Discusses Strategic Refocus on In Vivo Cell Therapy for Solid Tumors and Pausing of Phase III Heme Study Transcript
2 months ago benzinga.com
Crude Oil Moves Higher; US Factory Orders Rise In July
U.S. stocks rose mid-session, led by materials; factory orders beat estimates. Linkhome, Purple Biotech and GitLab surged, while Tscan and Credo fell.
2 months ago benzinga.com
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
TScan Therapeutics Inc. (NASDAQ:TCRX) on Wednesday announced a major corporate reorganization to prioritize its in vivo solid tumor pipeline, prompting a workforce reduction of approximately 75%.
2 months ago benzinga.com
TScan Reorganizes Pipeline Priorities, Implements Workforce Reduction
The strategic pivot focuses TScan's efforts on developing in vivo-engineered TCR-T therapies.
2 months ago benzinga.com
Dow Surges Over 200 Points; Ollie's Bargain Outlet Shares Gain After Q2 Earnings
U.S. stocks edged higher, led by the Dow and materials. Ollie’s beat EPS estimates; biotech and AI shares surged, while Tscan plunged 26%.
2 months ago globenewswire.com
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors
Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1…
2 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers BioVie (NASDAQ:BIVI) stock increased by 15.7% to $1.55 during Wednesday's after-market session. The market value of their outstanding shares is at $7.2 million. The company's, Q4 earnings…
-
2 months ago benzinga.com
Amgen To Terminate Research Collaboration And License Agreement With TScan Therapeutics; Termination Of Collaboration Agreement Effective November 10, 2026
On August 12, 2026, TScan Therapeutics, Inc. (the "Company") received notice from Amgen Inc. ("Amgen") of its election to terminate, in its entirety, the Research Collaboration and License Agreement,
-
2 months ago benzinga.com
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates TScan Therapeutics (NASDAQ:TCRX) with a Buy and maintains $7 price target.
2 months ago zacks.com
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago.
-
2 months ago benzinga.com
TScan Therapeutics Q2 EPS $(0.23) Misses $(0.21) Estimate, Sales $1.051M Miss $1.667M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent. This is a 17.86 percent increase over losses of…
2 months ago globenewswire.com
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
First patient dosed in Phase 3 ALLOHA-2™ study; topline readout expected mid-2028 Shared positive initial data from Cohort C of Phase 1 ALLOHA™ study, validating internal commercial-ready…
3 months ago globenewswire.com
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies
WALTHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
4 months ago globenewswire.com
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
WALTHAM, Mass., June 24, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
-
4 months ago benzinga.com
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.
-
4 months ago benzinga.com
TScan Says Cancer Therapy Data Support Move to Phase 3 Trial
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
4 months ago globenewswire.com
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation
11 of 14 patients dosed had complete donor chimerism within ~three weeks of receiving first infusion of TSC-101; an additional two had improving chimerism following TSC-101
5 months ago gurufocus.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology c
-
5 months ago benzinga.com
TScan Therapeutics Partners With Cellares To Evaluate Automated Clinical Manufacturing Of TSC-101, The Company's Lead TCR-T Therapy Candidate For Patients With Acute Myeloid Leukemia And Myelodysplastic Syndromes
Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T…
5 months ago businesswire.com
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies
SOUTH SAN FRANCISCO, Calif. & WALTHAM, Mass.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), and TScan Therapeutics, Inc. (Nasdaq: TCRX), a…
6 months ago zacks.com
TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.22 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.26 per share a year ago.
-
6 months ago benzinga.com
TScan Therapeutics Q1 EPS $(0.22) Misses $(0.20) Estimate, Sales $982.000K Miss $2.500M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.20) by 10 percent. This is a 15.38 percent increase over losses of…
6 months ago globenewswire.com
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Early data on patients treated in Cohort C of the ALLOHA™ Phase 1 heme trial expected in the second quarter of 2026 Initiation of Phase 3 study of TSC-101 (ALLOHA-2 ™ ) planned for the second quarter…
6 months ago globenewswire.com
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting
WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
6 months ago globenewswire.com
TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T…
7 months ago benzinga.com
12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Health Care Stocks Moving In Friday's Pre-Market Session
-
8 months ago benzinga.com
Wedbush Maintains Outperform on TScan Therapeutics, Raises Price Target to $5
Wedbush analyst David Nierengarten maintains TScan Therapeutics (NASDAQ:TCRX) with a Outperform and raises the price target from $4 to $5.
8 months ago zacks.com
TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $0.29 per share a year ago.
8 months ago benzinga.com
Earnings Breakdown: TScan Therapeutics Q4
Earnings Breakdown: TScan Therapeutics Q4
-
8 months ago benzinga.com
TScan Therapeutics Q4 EPS $(0.18) Beats $(0.24) Estimate, Sales $2.567M Beat $2.048M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.24) by 26.53 percent. This is a 37.93 percent increase over losses of…
8 months ago globenewswire.com
TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Presented positive updated data from the ALLOHA ™ Phase 1 heme trial at 67 th American Society of Hematology (ASH) Annual Meeting and Exposition Announced completion of enrollment in Cohort C of…
-
8 months ago benzinga.com
TScan Therapeutics Completes Enrollment Into Cohort C Of ALLOHA Study
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing processReceived FDA clearance of INDs for TSC-102-A01 and TSC-102-A03…
8 months ago globenewswire.com
TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03
Completed enrollment of Cohort C in the Phase 1 ALLOHA™ trial; patients to be treated with commercial-ready manufacturing process
8 months ago globenewswire.com
TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
WALTHAM, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell…
8 months ago defenseworld.net
TScan Therapeutics, Inc. (NASDAQ:TCRX) Receives Consensus Recommendation of “Hold” from Brokerages
TScan Therapeutics, Inc. (NASDAQ: TCRX - Get Free Report) has received an average rating of "Hold" from the seven ratings firms that are currently covering the firm, MarketBeat Ratings reports. One…
-
8 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
9 months ago benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
12 Health Care Stocks Moving In Friday's After-Market Session
-
11 months ago benzinga.com
TScan Therapeutics Announced Saturday, Updated Data from the ALLOHA Phase 1 Heme Trial; 3/3 Of TSC-101-treated Patients Who Reached Two-year Follow-up Remained Relapse-free Vs. 1/4 In Control Arm
TScan Therapeutics, Inc. (NASDAQ:TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients…
-
11 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
11 months ago benzinga.com
HC Wainwright & Co. Maintains Buy on TScan Therapeutics, Lowers Price Target to $7
HC Wainwright & Co. analyst Andres Y. Maldonado maintains TScan Therapeutics (NASDAQ:TCRX) with a Buy and lowers the price target from $10 to $7.
-
11 months ago benzinga.com
TScan Therapeutics Q3 EPS $(0.28) Beats $(0.30) Estimate, Sales $2.511M Beat $1.980M Estimate
TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.30) by 5.41 percent. This is a 12 percent decrease over losses of…